Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the company’s development of TRP-8803.
Fibromyalgia is a disease known widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. So far the existing treatments have limited efficacy and significant side effects. There are fewer than 10% of patients adhere to approved treatments after one year. Tryp noted that roughly 30% of these patients take opioids despite the lack of evidence for efficacy and the risk of addiction and/or overdose.
“Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs,” said CEO Jim Gilligan. “We are methodically expanding our patent portfolio and remain committed to developing a combined psychedelic and psychotherapy treatment for patients suffering the debilitating effects of conditions such as fibromyalgia and Binge Eating Disorder.”
Tryp said it is preparing for a Phase 2a clinical trial in collaboration with the University of Michigan to investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia. The clinical studies are expected to reinforce the positive preclinical results obtained by Tryp in an animal model of nociplastic pain. Once issued, the new patent will provide Tryp with Intellectual Property Protection for fibromyalgia utilizing its psilocybin-based candidates.
Tryp said in a statement that it is utilizing TRP-8802 to evaluate the use of psilocybin-related compounds in certain neuropsychiatric disorders in early-stage trials. TRP-8803 is the company’s lead drug and it includes a unique formulation that enhances the positive effects of psilocybin and psilocybin-related compounds, while reducing the limitations of psilocybin dosed through other routes of administration, including oral, nasal, and sublingual.